Last edition
News about "Stephen Chambers"
Helex Raises USD 3.5 Million in Seed Round to Advance Non-Viral Gene Therapies for Kidney Diseases
The new funding will support the development of Helex’s lead programme for ADPKD toward IND enabling studies, pipeline expansion leveraging its programmable LNP delivery and AI-based drug design platforms. The company is steadfast in building a robust franchise of renal programmes that profoundly improve and impact the lives of patients.
Stephen Chambers | 01/11/2025 | By Dineshwori | 270
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy